دورية أكاديمية
أعرض في EDS

NUSAP1 Promotes Immunity and Apoptosis by the SHCBP1/JAK2/STAT3 Phosphorylation Pathway to Induce Dendritic Cell Generation in Hepatocellular Carcinoma.

التفاصيل البيبلوغرافية
العنوان: NUSAP1 Promotes Immunity and Apoptosis by the SHCBP1/JAK2/STAT3 Phosphorylation Pathway to Induce Dendritic Cell Generation in Hepatocellular Carcinoma.
المؤلفون: Chen G; Medical School of Nantong University, Nantong, Jiangsu, China.; Clinical Laboratory, Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, Jiangsu, China., Li W; Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China., Ge R; Clinical Laboratory, Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, Jiangsu, China., Guo T; Clinical Laboratory, Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, Jiangsu, China., Zhang Y; The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China., Zhou C; Laboratory Department, Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, Jiangsu, China., Lin M; Clinical Laboratory, Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, Jiangsu, China.
المصدر: Journal of immunotherapy (Hagerstown, Md. : 1997) [J Immunother] 2024 Jul 09. Date of Electronic Publication: 2024 Jul 09.
Publication Model: Ahead of Print
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9706083 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-4513 (Electronic) Linking ISSN: 15249557 NLM ISO Abbreviation: J Immunother Subsets: MEDLINE
أسماء مطبوعة: Publication: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: Hagerstown, MD : Lippincott-Raven, c1997-
مستخلص: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and is associated with high morbidity and mortality rates. The aims of this study were to investigate the immune-promoting action of nucleolar and spindle-associated protein 1 (NUSAP1) and identify an immunotherapy target for HCC. The Cancer Genome Atlas (TCGA) was used to analyze interaction molecules and immune correlation. The interaction between NUSAP1 and SHC binding and spindle associated 1 (SHCBP1) was examined. The role of the SHCBP1/Janus kinase 2/signal transducer and activator of transcription 3 (SHCBP1/JAK2/STAT3) pathway in this process was explored. After co-culture with HCC cell lines, the differentiation of peripheral blood mononuclear cells (PBMCs) into dendritic cells (DC) was evaluated by measuring the expression of surface factors CD1a and CD86. Pathological tissues from 50 patients with HCC were collected to validate the results of cell experiments. The expression levels of CD1a and CD86 in tissues were also determined. The results show that NUSAP1 interacted with SHCBP1 and was positively correlated with DC. In HCC cell lines, an interaction was observed between NUSAP1 and SHCBP1. It was verified that NUSAP1 inhibited the JAK2/STAT3 phosphorylation pathway by blocking SHCBP1. After co-culture, the levels of CD1a and CD86 in PBMC were elevated. In the clinical specimens, CD1a and CD86 expression levels were significantly higher in the high-NUSAP1 group versus the low-NUSAP1 group. In Summary, NUSAP1 enhanced immunity by inhibiting the SHCBP1/JAK2/STAT3 phosphorylation pathway and promoted DC generation and HCC apoptosis. NUSAP1 may be a target of immunotherapy for HCC.
Competing Interests: The authors declare no conflicts of interest.
(Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
References: Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.
Marquardt JU, Andersen JB, Thorgeirsson SS. Functional and genetic deconstruction of the cellular origin in liver cancer. Nat Rev Cancer. 2015;15:653–667.
Maomao C, He L, Dianqin S, et al. Current cancer burden in China: Epidemiology, etiology, and prevention. Cancer Biol Med. 2022;19:1121–1138.
Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.
Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–1314.
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390.
Ikeda M, Mitsunaga S, Ohno I, et al. Systemic chemotherapy for advanced hepatocellular carcinoma: Past, present, and future. Diseases. 2015;3:360–381.
Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet (London England). 2002;359:1734–1739.
Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–1171.
Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37:429–442.
Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–1173.
Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66.
Hasegawa K, Kokudo N, Makuuchi M, et al. Comparison of resection and ablation for hepatocellular carcinoma: A cohort study based on a japanese nationwide survey. J Hepatol. 2013;58:724–729.
Lu LC, Cheng AL, Poon RT. Recent advances in the prevention of hepatocellular carcinoma recurrence. Seminars in Liver Disease. Thieme Medical Publishers; 2014.
Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: From t cell basic science to clinical practice. Nat Rev Immunol. 2020;20:651–668.
Wang DR, Wu XL, Sun YL. Therapeutic targets and biomarkers of tumor immunotherapy: Response versus non-response. Signal Transduct Target Ther. 2022;7:331.
Abbas AK, Lichtman AH, Pillai S, et al. Cellular and Molecular Immunology, 10th ed. Philadelphia, PA, USA: Elsevier; 2022. ISBN 978-0-323-75748-5.
Chaplin DD. Overview of the immune response. J Allergy Clin Immunol. 2010;125:S3–S23.
Chen L, Yang L, Qiao F, et al. High levels of nucleolar spindle associated protein and reduced levels of BRCA1 expression predict poor prognosis in triple-negative breast cancer. PLoS One. 2015;10:e0140572.
Bogunovic D, O’Neill DW, Belitskaya-Levy I, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A. 2009;106:20429–20434.
Hou S, Hua L, Wang W, et al. Nucleolar spindle associated protein 1 (NUSAP1) facilitates proliferation of hepatocellular carcinoma cells. Transl Cancer Res. 2019;8:2113–2120.
Liu K, Hao M, Ouyang Y, et al. CD133(+) cancer stem cells promoted by VEGF accelerate the recurrence of hepatocellular carcinoma.. Sci Rep. 2017;7:41499.
Wu X, Xu B, Yang C, et al. Nucleolar and spindle associated protein 1 promotes the aggressiveness of astrocytoma by activating the hedgehog signaling pathway. J Exp Clin Cancer Res. 2017;36:127.
Gordon CA, Gong X, Ganesh D, et al. NUSAP1 promotes invasion and metastasis of prostate cancer. Oncotarget. 2017;8:29935–29950.
Pan S, Zhan Y, Chen X, et al. Identification of biomarkers for controlling cancer stem cell characteristics in bladder cancer by network analysis of transcriptome data stemness indices. Front Oncol. 2019;9:613.
Zeng H, Ji J, Song X, et al. Stemness related genes revealed by network analysis associated with tumor immune microenvironment and the clinical outcome in lung adenocarcinoma. Front Genet. 2020;11:549213.
Li H, Zhang W, Yan M, et al. Nucleolar and spindle associated protein 1 promotes metastasis of cervical carcinoma cells by activating Wnt/beta-catenin signaling.. J Exp Clin Cancer Res. 2019;38:33.
Wang J, Sun J, Liu LN, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019;25:656–666.
Ravi R, Noonan KA, Pham V, et al. Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the effiffifficacy of cancer immunotherapy.. Nat Commun. 2018;9:741.
Wang N, Zhu L, Wang L, et al. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers. Comput Struct Biotechnol J. 2022;20:3106–3119.
Liu M, Li C, Qu J, et al. Baicalein enhances immune response in TNBC by inhibiting leptin expression of adipocytes. Cancer Sci. 2023;114:3834–3847.
Chuangchot N, Jamjuntra P, Yangngam S, et al. Enhancement of PD-L1-attenuated CAR-T cell function through breast cancer-associated fibroblasts-derived IL-6 signaling via STAT3/AKT pathways. Breast Cancer Res. 2023;25:86.
Qiu X, Zhou J, Xu H, et al. Alcohol reshapes a liver premetastatic niche for cancer by extra- and intrahepatic crosstalk-mediated immune evasion. Mol Ther. 2023;31:2662–2680.
Anstee Joanne E, Feehan Karen T, Opzoomer James W, et al. LYVE-1 macrophages form a collaborative CCR5-dependent perivascular niche that influences chemotherapy responses in murine breast cancer. Dev Cell. 2023;58:1548–1561.e10.
Kim S, Chen J, Jo S, et al. IL-6 selectively suppresses cDC1 specification via C/EBPβ. J Exp Med. 2023;220.
Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity. 2013;39:49–60.
Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134–144.
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.
Ferrone C, Dranoff G. Dual roles for immunity in gastrointestinal cancers. J Clin Oncol. 2010;28:4045–4051.
Zhang GY, Ma ZJ, Wang L, et al. The role of Shcbp1 in signaling and disease. Curr Cancer Drug Targets. 2019;19:854–862.
Asano E, Hasegawa H, Hyodo T, et al. SHCBP1 is required for midbody organization and cytokinesis completion. Cell Cycle. 2014;13:2744–2751.
Leonard WJ, O’Shea JJ. Jaks and STATs: Biological implications. Annu Rev Immunol. 1998;16:293–322.
O’Shea JJ. Jaks, STATs, cytokine signal transduction, and immunoregulation: Are we there yet? Immunity. 1997;7:1–11.
Hou XS, Perrimon N. The JAK-STAT pathway in drosophila. Trends Genet. 1997;13:105–110.
Barrat FJ, Crow MK, Ivashkiv LB. Interferon target-gene expression and epigenomic signatures in health and disease. Nat Immunol. 2019;20:1574–1583.
Meraz MA, White JM, Sheehan KC, et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell. 1996;84:431–442.
Golus M, Bugajski P, Chorbinska J, et al. STAT3 and its pathways’ dysregulation-underestimated role in urological tumors. Cells. 2022;11:3024.
Amaya ML, Inguva A, Pei S, et al. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation. Blood. 2022;139:584–596.
Dudziak D, Kamphorst AO, Heidkamp GF, et al. Differential antigen processing by dendritic cell subsets in vivo. Science. 2007;315:107–111.
Joffre OP, Segura E, Savina A, et al. Cross-presentation by Dendritic Cells. Nat Rev Immunol. 2012;12:557–569.
van Endert P. Intracellular recycling and cross-presentation by MHC class I molecules. Immunol Rev. 2016;272:80–96.
Amigorena S. Editorial overview: usual and unusual ways to antigen presentation. Curr Opin Immunol. 2020;64:iii–iv.
Roquilly A, Mintern JD, Villadangos JA. Spatiotemporal adaptations of macrophage and dendritic cell development and function. Annu Rev Immunol. 2022;40:525–557.
Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56–61.
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–1355.
Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8:328rv4.
June CH, Sadelain M. Chimeric antigen receptor therapy. New England Journal of Medicine. 2018;379:64–73.
Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science. 2018;359:1355–1360.
Kokje VBC, Gabel G, Koole D, et al. IL-6: a Janus-like factor in abdominal aortic aneurysm disease. Atherosclerosis. 2016;251:139–146.
Munoz-Canoves P, Scheele C, Pedersen BK, et al. Interleukin-6 myokine signaling in skeletal muscle: A double-edged sword? FEBS J. 2013;280:4131–4148.
Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235–238.
Kimura A, Naka T, Kishimoto T. IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci. 2007;104:12099–12104.
Veldhoen M, Hocking RJ, Atkins CJ, et al. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24:179–189.
تواريخ الأحداث: Date Created: 20240709 Latest Revision: 20240709
رمز التحديث: 20240709
DOI: 10.1097/CJI.0000000000000531
PMID: 38980111
قاعدة البيانات: MEDLINE
الوصف
تدمد:1537-4513
DOI:10.1097/CJI.0000000000000531